

UPDATED URGENT FIELD SAFETY NOTICE

HEMOSIL® LIQUID ANTI-XA, PART NO. 0020302601 ALL LOTS ACL TOP® FAMILY / ACL TOP® FAMILY 50 SERIES

March, 2023

Dear Valued HemosIL Liquid Anti-Xa Customer:

This notification is intended to advise your facility regarding an on-board instrument stability issue that affects all currently released lots, as well as future lots, of HemosIL Liquid Anti-Xa (0020302601) on the ACL TOP Family and ACL TOP Family 50 Series hemostasis testing systems.

Below is a list of all in-date product lots:

| Product Name | Part No. | Lot No. | Exp. Date |
|------------------------|------------|----------|------------|
| HemosIL Liquid Anti-Xa | 0020302601 | N1007812 | 04/30/2023 |
| | | N0513383 | 11/30/2023 |
| | | N0715001 | 01/31/2024 |
| | | N1016744 | 04/30/2024 |
| | | N0229907 | 08/31/2024 |
| | | N0723871 | 01/31/2025 |
| | | N0825047 | 02/28/2025 |

• Issue Description and Results Impact

We have internally identified that HemosIL Liquid Anti-Xa (Part No. 0020302601) is not meeting its labeled on-board instrument stability claim for the heparin assay of 7 days at 15-25°C for the ACL TOP Family and ACL TOP Family 50 Series. Initial testing supported a 5 day on-board stability claim, documented in our previous notification dated August 25, 2021; however, we received clearance for the HemosIL Liquid Anti-Xa with a reduced stability claim of 4 days at 15-25°C.

There are no known customer complaints to date. However, if an erroneous heparin result were to occur, there is a risk that a dose adjustment could be made if the result was to exceed an Anti-Xa threshold as defined by the internal procedures. The harm would be limited to risks associated with blood collection rather than a more serious complication.

• Customer Actions

At this time, we are updating the previous notification, dated August 25, 2021, of on-board stability reduction from 7 days to 5 days. The **on-board instrument stability claim has been reduced to 4 days** for **all in-date and future product lots** of HemosIL Liquid Anti-Xa (Part No. 0020302601) on the ACL TOP Family and ACL TOP Family 50 Series. Please use the reduced on-board stability until a new ACL TOP Family/ACL TOP Family 50 Series Test Parameter reflecting this change is available.

Please take the following **immediate** actions:

• <u>Use</u> the following **reduced on-board instrument stability claim** for HemosIL Liquid Anti-Xa (Part No. 0020302601) on the **ACL TOP Family and ACL TOP Family 50 Series**.

| ACL TOP Family and ACL TOP Family 50 Series | | |
|--|---------------------------------------|--|
| <u>Current</u> On-board Instrument Stability | Reduced On-board Instrument Stability | |
| 5 Days | 4 Days | |

- Run quality controls on ACL TOP Family and ACL TOP Family 50 Series before patient testing or every 8 hours and with each new vial in accordance with good laboratory practice.
- Post this notification on each of your ACL TOP Family / ACL TOP Family 50 Series instruments.
- <u>Share</u> this information with your staff, notifying them of the reduced on-board stability requirement of 4 Days for the ACL TOP Family and ACL TOP Family 50 Series.
- Retain a copy of this letter in your files as a record of the notification.

Please contact your local representative with any questions.

We appreciate your prompt attention to this important notification.

Sincerely,

Anuja Khan Regulatory Affairs Manager II